Nature’s Sunshine leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Immunogen, AVEO Pharmaceuticals and Alnylam Pharmaceuticals.
DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on developing new cancer therapies, today announced the formalization of an agreement with PRA Health Sciences (Nasdaq: PRAH), a leading contract research organization (CRO) to conduct the Company’s Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces plans for research and formulation development (“R&D”) on nonsteroidal anti-inflammatory drugs (“NSAIDs”) utilizing its patented technology and as provisioned within its previously announced 2017 & 2018 R&D program.
Oncolytics Biotech announced the US Food and Drug Administration granted a fast track designation for Reolysin, an immuno-oncology viral agent treating metastatic breast cancer.
Sorrento Therapeutics announced the completion of a manufacturing facility in China, which will be dedicated to supporting Sorrento’s antibody drug conjugate pipeline.
By Jocelyn Aspa
Digi International (NASDAQ:DGII) has announced the introduction of Digi SafeTemps.
As quoted in the press release:
Designed in conjunction with leading transportation and logistics companies, Digi SafeTemps provides precise and continuous visibility using wireless monitors that automatically generate temperature alerts and reports of perishable goods throughout the transportation and supply chain process.
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) (OTCQB: LXRP) (CSE: LXX)(CSE: LXX.CN)(CNSX: LXX) (the “Company”, “Lexaria”) announces a $1 million combined research and development (“R&D”) and intellectual property (“IP”) budget.